Impact of Oral Ibandronate 150 mg Monthly on Structural Properties of Bone in Postmenopausal Osteoporosis (SPIMOS-3D)
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
Efficacy:
To investigate changes of structural bone properties in vivo using 3DpQCT ("Xtreme" CT,
Scanco) in monthly oral ibandronate therapy for women with postmenopausal osteoporosis.
Major structural bone parameters which determine bone strength and predict fracture risk
earlier and more precisely are measurable in vivo by 3DpQCT.
Safety:
To assess the tolerability and safety of ibandronate therapy
Phase:
Phase 4
Details
Lead Sponsor:
Charite University, Berlin, Germany
Treatments:
Calcium Calcium, Dietary Diphosphonates Ergocalciferols Ibandronic Acid Vitamin D Vitamins